|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FZD1 |
Gene summary for FZD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FZD1 | Gene ID | 8321 |
| Gene name | frizzled class receptor 1 | |
| Gene Alias | FZD1 | |
| Cytomap | 7q21.13 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q9UP38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8321 | FZD1 | P2T-E | Human | Esophagus | ESCC | 1.50e-13 | 2.43e-01 | 0.1177 |
| 8321 | FZD1 | P4T-E | Human | Esophagus | ESCC | 5.08e-12 | 7.94e-02 | 0.1323 |
| 8321 | FZD1 | P5T-E | Human | Esophagus | ESCC | 7.71e-08 | 2.90e-02 | 0.1327 |
| 8321 | FZD1 | P8T-E | Human | Esophagus | ESCC | 1.15e-05 | 9.79e-03 | 0.0889 |
| 8321 | FZD1 | P9T-E | Human | Esophagus | ESCC | 1.01e-07 | 1.24e-02 | 0.1131 |
| 8321 | FZD1 | P10T-E | Human | Esophagus | ESCC | 1.88e-19 | 3.96e-01 | 0.116 |
| 8321 | FZD1 | P11T-E | Human | Esophagus | ESCC | 1.10e-05 | 3.04e-01 | 0.1426 |
| 8321 | FZD1 | P12T-E | Human | Esophagus | ESCC | 5.80e-13 | 1.29e-01 | 0.1122 |
| 8321 | FZD1 | P15T-E | Human | Esophagus | ESCC | 2.81e-05 | 2.98e-01 | 0.1149 |
| 8321 | FZD1 | P16T-E | Human | Esophagus | ESCC | 1.85e-83 | 2.17e+00 | 0.1153 |
| 8321 | FZD1 | P20T-E | Human | Esophagus | ESCC | 1.08e-04 | -2.87e-02 | 0.1124 |
| 8321 | FZD1 | P21T-E | Human | Esophagus | ESCC | 1.12e-07 | -1.04e-02 | 0.1617 |
| 8321 | FZD1 | P23T-E | Human | Esophagus | ESCC | 2.19e-02 | 1.26e-01 | 0.108 |
| 8321 | FZD1 | P26T-E | Human | Esophagus | ESCC | 5.71e-20 | 1.62e-01 | 0.1276 |
| 8321 | FZD1 | P27T-E | Human | Esophagus | ESCC | 1.75e-10 | 1.03e-01 | 0.1055 |
| 8321 | FZD1 | P28T-E | Human | Esophagus | ESCC | 1.18e-03 | -3.24e-02 | 0.1149 |
| 8321 | FZD1 | P31T-E | Human | Esophagus | ESCC | 3.39e-26 | 1.76e-01 | 0.1251 |
| 8321 | FZD1 | P32T-E | Human | Esophagus | ESCC | 2.11e-09 | 6.30e-02 | 0.1666 |
| 8321 | FZD1 | P36T-E | Human | Esophagus | ESCC | 3.65e-02 | 1.94e-03 | 0.1187 |
| 8321 | FZD1 | P37T-E | Human | Esophagus | ESCC | 6.17e-05 | 3.27e-02 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
| GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00488638 | Esophagus | ESCC | stem cell differentiation | 122/8552 | 206/18723 | 5.95e-05 | 4.59e-04 | 122 |
| GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:003090118 | Esophagus | ESCC | midbrain development | 58/8552 | 90/18723 | 2.52e-04 | 1.55e-03 | 58 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | Cervix | ADJ |
| WNT5B | FZD1 | WNT5B_FZD1 | ncWNT | CRC | AD |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | CRC | MSI-H |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | Esophagus | ESCC |
| WNT5A | FZD10 | WNT5A_FZD10 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD1 | WNT5B_FZD1 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | Esophagus | ESCC |
| WNT10A | FZD10_LRP6 | WNT10A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT10B | FZD10_LRP6 | WNT10B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT2 | FZD10_LRP6 | WNT2_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT2B | FZD10_LRP6 | WNT2B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT3A | FZD10_LRP6 | WNT3A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT7B | FZD10_LRP6 | WNT7B_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT9A | FZD10_LRP6 | WNT9A_FZD10_LRP6 | WNT | Esophagus | ESCC |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | HNSCC | OSCC |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | HNSCC | Precancer |
| WNT5B | FZD1 | WNT5B_FZD1 | ncWNT | Lung | IAC |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | Skin | cSCC |
| WNT5A | FZD1 | WNT5A_FZD1 | ncWNT | THCA | Cancer |
| WNT2 | FZD1_LRP5 | WNT2_FZD1_LRP5 | WNT | THCA | Cancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FZD1 | SNV | Missense_Mutation | rs749347940 | c.1069N>A | p.Phe357Ile | p.F357I | Q9UP38 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| FZD1 | SNV | Missense_Mutation | rs752224375 | c.1763N>A | p.Gly588Glu | p.G588E | Q9UP38 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FZD1 | SNV | Missense_Mutation | novel | c.859A>C | p.Asn287His | p.N287H | Q9UP38 | protein_coding | tolerated(0.3) | benign(0.017) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| FZD1 | insertion | Frame_Shift_Ins | novel | c.1183_1184insTGGCTATGGGATCTTGTACAAATTACTT | p.Gln395LeufsTer97 | p.Q395Lfs*97 | Q9UP38 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FZD1 | SNV | Missense_Mutation | novel | c.326N>G | p.Ser109Cys | p.S109C | Q9UP38 | protein_coding | deleterious(0.01) | possibly_damaging(0.894) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FZD1 | SNV | Missense_Mutation | novel | c.1560N>A | p.Met520Ile | p.M520I | Q9UP38 | protein_coding | tolerated(0.68) | benign(0.074) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| FZD1 | SNV | Missense_Mutation | rs751566731 | c.341G>A | p.Gly114Asp | p.G114D | Q9UP38 | protein_coding | deleterious(0.03) | possibly_damaging(0.609) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FZD1 | SNV | Missense_Mutation | c.440G>A | p.Gly147Asp | p.G147D | Q9UP38 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FZD1 | SNV | Missense_Mutation | novel | c.1828A>T | p.Thr610Ser | p.T610S | Q9UP38 | protein_coding | tolerated(0.44) | benign(0.241) | TCGA-A6-6782-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FZD1 | SNV | Missense_Mutation | novel | c.1219A>G | p.Met407Val | p.M407V | Q9UP38 | protein_coding | tolerated(0.09) | probably_damaging(0.919) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8321 | FZD1 | G PROTEIN COUPLED RECEPTOR, CELL SURFACE, KINASE | GNF-PF-3411 | CHEMBL593726 | 23453073 | |
| 8321 | FZD1 | G PROTEIN COUPLED RECEPTOR, CELL SURFACE, KINASE | NICLOSAMIDE | NICLOSAMIDE | 23453073 | |
| 8321 | FZD1 | G PROTEIN COUPLED RECEPTOR, CELL SURFACE, KINASE | TCMDC-124051 | CHEMBL464249 | 23453073 | |
| 8321 | FZD1 | G PROTEIN COUPLED RECEPTOR, CELL SURFACE, KINASE | antagonist | CHEMBL2364652 | VANTICTUMAB | |
| 8321 | FZD1 | G PROTEIN COUPLED RECEPTOR, CELL SURFACE, KINASE | antibody | 381118907 | VANTICTUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |